Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: SHR-1316 at a dose 20mg/kg q3w|DRUG: SHR6390 at a dose of 150mg orally, daily|RADIATION: SBRT
Sponsor: Shengjing Hospital
Collaborators: Jiangsu HengRui Medicine Co., Ltd.